Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal ACWY conjugate vaccine + pneumococcal conjugate vaccine 13-valent
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This combination refers to the co-administration of the quadrivalent meningococcal conjugate vaccine (MenACWY) and the 13-valent pneumococcal conjugate vaccine (PCV13). MenACWY vaccines, such as Menveo, Nimenrix, and MenQuadfi, provide protection against *Neisseria meningitidis* serogroups A, C, W, and Y, which are major causes of bacterial meningitis and septicemia. PCV13, marketed as Prevnar 13, targets 13 serotypes of *Streptococcus pneumoniae* (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) responsible for invasive pneumococcal disease, pneumonia, and otitis media. Both vaccines utilize conjugation technology, where bacterial capsular polysaccharides are chemically linked to a carrier protein (typically CRM197 or tetanus toxoid) to convert the T-cell independent polysaccharide antigens into T-cell dependent antigens, thereby inducing immunological memory and high antibody titers in infants and young children. They are frequently administered concomitantly during routine pediatric vaccination visits.
- Brand names
- Prevnar 13Prevnar13Prevnar-13MenveoMenQuadfiNimenrixMenactra
- Other names
- MenACWY + PCV13meningococcal group A, C, W135, and Y conjugate vaccine + pneumococcal 13-valent conjugate vaccine
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)Type 1 CPS (Streptococcus pneumoniae serotype 1 capsular polysaccharide)CPS14 (Streptococcus pneumoniae serotype 14 capsular polysaccharide)CPS 18C (Streptococcus pneumoniae capsular polysaccharide serotype 18C)19A CPS (Streptococcus pneumoniae serotype 19A capsular polysaccharide)Streptococcus pneumoniae serotype 19F capsular polysaccharideStreptococcus pneumoniae serotype 23F capsular polysaccharidePPS3 (Streptococcus pneumoniae serotype 3 capsular polysaccharide)ST4 CPS (Streptococcus pneumoniae serotype 4 capsular polysaccharide)Streptococcus pneumoniae serotype 5 capsular polysaccharide6A CPS (Streptococcus pneumoniae serotype 6A capsular polysaccharide)6B CPS (Streptococcus pneumoniae serotype 6B capsular polysaccharide)7F CPS (Streptococcus pneumoniae serotype 7F capsular polysaccharide)9V CPS (Streptococcus pneumoniae serotype 9V capsular polysaccharide)
Beyond the preview
Go deeper on meningococcal ACWY conjugate vaccine + pneumococcal conjugate vaccine 13-valent.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal ACWY conjugate vaccine + pneumococcal conjugate vaccine 13-valent.